Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Tumor Suppressor Protein Targets Liver Cancer

By Salk Institute | March 29, 2018

Salk Institute scientists, together with researchers from Switzerland’s University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer. The tumor suppressor, which could be useful as a biomarker to help diagnose and monitor treatment for liver cancer, could also be relevant for other cancer types. The work appeared in print in the journal Nature on March 29, 2018, and adds to the growing body of knowledge about cellular processes that either promote or prevent cancer.

“I think we’ve discovered a new control mechanism for cell proteins that, when disrupted, could be a driver for cancer,” says Tony Hunter, Salk’s American Cancer Society Professor and an author on the new paper. “It’s exciting because it offers the possibility of new therapeutics or new diagnostics for a cancer that’s basically untreatable–liver cancer–and potentially others, as well.”

Hunter is known for his 1979 discovery of a molecular signaling process called tyrosine phosphorylation. In this process, proteins called kinases attach the chemical phosphate–like a sticky note–to the amino acid tyrosine in target proteins. But, when dysfunctional, tyrosine phosphorylation can also turn on the uncontrolled cell growth that leads to cancer. Hunter’s breakthrough opened the door to the development of a new class of anti-cancer pharmaceuticals called tyrosine kinase inhibitors, including the life-saving leukemia drug Gleevec.

Since then, Hunter’s lab has continued to study the process of phosphorylation, not only in terms of adding phosphates (via kinases or “on switches”) but also removing them (via proteins called phosphatases or “off switches”). In 2015, his team developed an antibody to identify and study phosphates bonded to another amino acid called histidine.

In the new work, the international team, led by Professor Michael Hall of the Biozentrum, University of Basel, examined these switches in a mouse model of the most common form of primary liver cancer–hepatocellular carcinoma. To compare tumor cells with normal cells, the team analyzed more than 4,000 proteins in healthy and diseased liver tissue. By the end, three proteins stood out: the histidine kinases NME1 and NME2 were elevated in tumor cells, and the suspected histidine phosphatase LHPP was deficient.

“It is striking that LHPP is present in healthy tissue and completely absent in tumor tissue,” says Sravanth Hindupur, a postdoctoral researcher at the University of Basel and the paper’s first author. That gave the researchers a clue to explore histidine phosphorylation as a potential cancer target. Indeed, they found that the levels of protein phosphorylated in histidine were significantly higher in the tumor tissue than in normal liver tissue.

NME1 and NME2 are known histidine kinases and LHPP had been suspected to be a histidine phosphatase. With further experiments, the team verified that not only is LHPP a histidine phosphatase, but it is also a tumor suppressor–essentially an “off” switch for cancer. Reintroducing LHPP into the liver of the model mice destined to develop tumors prevented the formation of tumors.

When the researchers next examined samples from human liver tumors, they found a similar pattern: NME1 and 2 levels were high and LHPP was low compared to healthy liver tissue. Furthermore, the Cancer Genome Atlas database, a collection of RNA sequences obtained from different human cancers, showed that a significant fraction of human liver cancers have low levels of LHPP, and that both disease severity and life expectancy are correlated with LHPP levels.

“The parallels between tyrosine phosphorylation and histidine phosphorylation are what really got me interested in the project,” adds Hunter. “Whether this can be used as a therapeutic avenue, I don’t know. But the fact that it could be so disease-relevant motivates me.”

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE